Jun 09 2026

Future Neurology “Real-world insights into idiopathic hypersomnia symptoms, treatments, and quality of life from the ARISE study: a Plain Language Summary of Publication”

Logan D. Schneider, Amy Desmarais, Aatif M. Husain , Diane Ito, Douglas S. Fuller, Phyllis...

09:45 / News

Share

May 13 2026

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

DUBLIN--(BUSINESS WIRE)--May 12, 2026-- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled,...

08:23 / News

Share

May 08 2026

Wake Up Narcolepsy 2026 National Summit Recap

The Wake Up Narcolepsy (WUN) 2026 National Summit took place on April 25th, at the...

13:15 / News

Share

May 04 2026

Institute for Clinical and Economic Review Releases Evidence Report on Treatment for Narcolepsy

BOSTON, April 29, 2026 – The Institute for Clinical and Economic Review (ICER) today posted its revised Evidence...

08:22 / News

Share

Apr 17 2026

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

DUBLIN--(BUSINESS WIRE)--Apr. 16, 2026-- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the...

14:51 / News

Share

Apr 08 2026

2026 Narcolepsy Family Weekend Recap

Wake Up Narcolepsy (WUN)'s 2026 Family Weekend took place March 27th - 29th at the...

15:17 / News

Share

Apr 02 2026

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

DUBLIN--(BUSINESS WIRE)--Apr. 1, 2026-- Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a...

11:20 / News

Share

Apr 02 2026

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

INDIANAPOLIS and BOSTON and LONDON, March 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company...

08:38 / News

Share

Mar 30 2026

Join Us for April’s Brown Bag Webinar – Navigating Narcolepsy and Pregnancy

Join us on April 9th at 2pm ET for our next Brown Bag Webinar, “Navigating...

13:05 / News

Share

Feb 17 2026

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Feb. 17, 2026-- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug...

14:32 / News

Share